FDA Alleges Fraud as Tavneos Deaths Hit 20 in Japan
A $3.7 billion drug acquisition is unraveling: 20 deaths, a market withdrawal demand, and now FDA allegations of manipulated trial data.
A $3.7 billion drug acquisition is unraveling: 20 deaths, a market withdrawal demand, and now FDA allegations of manipulated trial data.
Boston Scientific paid $1.5B for 34% of MiRus and locked in a $3B option for its SIEGEL TAVR system, one year after scrapping its own valve program.
Enhertu's $5.4B annual sales projection grows with dual early breast cancer clearance, but patients who used it before surgery can't get it after.
BioMarin's $270M Inozyme bet just got complicated: BMN 401 hit the biomarker endpoint but missed skeletal healing and all secondary goals.
Adani Green sold $750M in bonds while its founder personally orchestrated bribe payments to Indian officials, the SEC alleged in late 2024.
CFPB just scrapped disparate impact under ECOA, but mortgage lenders and state AGs in New York, New Jersey, and Massachusetts won't play along.
Judge Barrett called Peters a 'charlatan' who'd do it again. Colorado's governor cut her 9-year sentence anyway, after just 18 months.
NYDFS is telling NY lenders that disparate impact still applies, directly contradicting Trump's EO 14281 and the CFPB's Regulation B rewrite.
Jules v. Balazs locks federal courts onto post-arbitration jurisdiction for stayed FAA cases, closing the Badgerow gap businesses feared.
Three malicious node-ipc versions drain cloud keys, SSH creds, and CI/CD tokens via DNS; attacker hijacked an inactive npm maintainer's account.
Three AI coding agents fell at Pwn2Own Berlin for $65K in prizes, and the patch window for Cursor and Codex won't close for 90 days.
FDIC's transaction-level data shows the $49M-threshold depositors who drained SVB in six days, and they ran at Signature and First Republic too.
Japanese startup Reqrea left 1 million hotel passports in a public S3 bucket anyone could read. Its investigation has no published timeline.
Drift and Kelp DAO lost nearly $600M in April. Cybersecurity experts now say the speed of those attacks is consistent with AI assistance.
When FDA's CDER chief exits and other senior roles turn over at once, pharma has a genuine question: who's running the review process.